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SHORT COMMUNICATION
Expression of c-erbB-2 protein product in bladder cancer
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There is considerable interest at present in the role of growth
factors, their receptors and other oncogene products in the
development and progression of human cancers. Alterations
in a variety of oncogenes have been reported in urological
malignancies (Russell et al., 1990). Approximately 10% of
bladder tumours have activated ras oncogenes (Fujita et al.,
1984; Malone et al., 1985), and there is an association
between expression of epidermal growth factor receptors
(EGFr, the c-erbB-1 proto-oncogene product) and muscle
invasive growth, poor differentiation and poor prognosis in
bladder cancer (Neal et al., 1985; Berger et al., 1987; Neal et
al., 1990).
The proto-oncogene c-erbB-2 encodes a transmembrane,
receptor-like protein which shows partial homology with the
EGFr molecule (Gullick & Venter, 1989). Its putative ligand
is unidentified, but studies using chimeric receptors indicate
that the cytoplasmic tyrosine kinase domain is capable of
producing signals leading to cell proliferation (Lee et al.,
1989). Amplification and/or overexpression of c-erbB-2 has
been demonstrated in a variety of human cancers (Gullick &
Venter, 1989) and in breast carcinoma appears to be associ-
ated with earlier relapse and shorter overall survival (Barnes,
1989). As part of a prospective study of bladder cancer, into
the relationship between clinical outcome and the expression
of growth factors and their receptors, we have assessed levels
of c-erbB-2 protein in a series of primary transitional cell
carcinomas, using an immunohistochemical technique.
Specimens were obtained from 44 consecutive patients (29
male and 15 female; median age 69 years (range 46-89)).
Twenty-four patients had superficial (pTa or pTl) tumours
(20 moderately differentiated, four poorly differentiated), and
20 had muscle invasive (pT2, pT3 or pT4) tumours (three
moderately differentiated, 17 poorly differentiated). Expres-
sion of the c-erbB-2 protein product was demonstrated using
a monoclonal antibody (NCL-CBI1) raised against a syn-
thetic peptide from the C-terminal end of the predicted pro-
tein sequence (Corbett et al., 1990). Part of the tumour was
snap frozen and stored at - 70°C. Frozen sections cut at
5pim were fixed in acetone for 10 min and incubated over-
night at 4°C with NCL-CBI1 (culture medium at a dilution
of 1:40). After adding rabbit anti-mouse peroxidase-
conjugated antiserum (Dako) diluted 1:20, the peroxidase
reaction was developed using diaminobenzidine as
chromagen, and sections were counterstained with haema-
toxylin. Tumours were scored by assessing both the intensity
of membrane staining (0, weak (+), strong (+ +) and the
proportion of cells showing such staining (0%, 1-49%,
50- 100%). Each staining run included, as a positive control,
a section from a strongly (+ +) staining breast carcinoma
known to have approximately 15-fold amplification of the
c-erbB-2 gene (Dr J.A. Henry, unpublished data). Negative
controls were prepared by staining duplicate sections of each
tumour using the method described above, but omitting the
primary antibody.
Correspondence: C. Wright.
Received 11 April 1990; and in revised form 16 July 1990.
Membrane staining (of variable intensity and extent) was
observed in 16 cases (36%), and these were evenly distributed
between superficial and invasive tumours (Table I), and
between moderately and poorly differentiated tumours (Table
II). In three tumours there was strong staining (comparable
in intensity to the positive control) of more than 90% of the
tumour cells (Figure 1); a further two cases showed intense
staining which was focal, involving less than 50% of the
tumour. Weak membrane positivity was observed in sections
from 11 tumours; this was diffuse in seven cases and focal in
four. Four of the five tumours with intensely staining cells
were muscle invasive; this association is not statistically
significant, but it is of interest that the fifth case was a pTa
tumour which progressed rapidly on follow-up. Sections of
non-dysplastic transitional epithelium from the bladders of
four patients did not show appreciable membrane staining.
The results of initial studies of c-erbB-2 in human neo-
plasia suggested that gene amplification and/or overexpres-
sion might be confined to adenocarcinomas (Tal et al., 1988),
but both amplification and overexpression have subsequently
been demonstrated in squamous cell carcinoma of bronchus
(Schneider et al., 1989; Weiner et al., 1990). The data pres-
ented here indicate that c-erbB-2 protein overexpression also
occurs in a significant proportion of carcinomas arising from
transitional epithelium of bladder; it would be reasonable to
conclude that such overexpression will be a feature of transi-
tional cell carcinomas arising at other sites. Using the
antibody 21N (Gullick et al., 1987) and formalin-fixed,
paraffin-embedded material, McCann et al. found membrane
staining in only one (2%) of 48 bladder carcinomas (McCann
et al., 1990). To assess the effect of formalin fixation on
c-erbB-2 protein product immunoreactivity, the paraffin
blocks for 15 of the cases in the current study were retrieved
and 5gtm sections stained, again using NCL-CBlI (1:40) and
an indirect immunoperoxidase method. Whereas six of these
tumours were diffusely positive (>75% cells staining) using
frozen sections, the corresponding paraffin sections showed
staining of a similar extent in only one case; three others
were focally positive (<25% cells staining) and two were
negative. The other nine cases, negative on frozen section,
were also negative using formalin-fixed, paraffin-embedded
material. Slamon's group have also noted decreased immuno-
histochemical reactivity for c-erbB-2 protein in formalin
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fixed, paraffin embedded samples, compared with frozen
material (Slamon et al., 1989).
There is now a considerable body of evidence supporting a
relationship between c-erbB-2 overexpression in breast cancer
and poorer prognosis (Barnes, 1989). In an immunohisto-
chemical study using the 21N antibody we found that this
relationship only held for the group of patients whose
tumours showed strong membrane staining; patients with
weakly staining tumours had similar relapse-free and overall
survival to those with negative tumours (Wright et al., 1989).
It is of interest, therefore, that four of the five bladder
tumours with intense membrane positivity were muscle
invasive; this suggests a need for a fuller evaluation of the
clinical significance of c-erbB-2 expression in bladder
tumours, with tollow-up studies on larger numbers of
patients. The biological significance of such expression is also
unclear. However, amplification of unaltered c-erbB-2 gene in
NIH 3T3 cells results in c-erbB-2 protein over-expression, cell
transformation and tumour formation in athymic mice (Hud-
ziak et al., 1987); and expression of the oncogene neu (the rat
homologue of the c-erbB-2 gene) in activated form in trans-
genic mice is associated with the development of mammary
carcinomas (Muller et al., 1988). A direct role for receptor
overexpression in accelerated tumour progression or in-
creased metastatic potential would raise the prospect of
intervening therapeutically using, for example, receptor
antibodies (Drebin et al., 1986).
In this series c-erbB-2 protein expression was observed in
only 16 of 44 bladder tumours, and the processes of initiation
and progression in transitional cell carcinoma almost cer-
tainly involve the complex interaction of a variety of
oncogenes (Russell et al., 1990). Death from bladder cancer
is associated with EGFr expression (Neal et al., 1990) and
determining the levels of growth factor receptors and other
oncogene products may allow us to predict prognosis more
accurately.
This study was supported by the North of England Cancer Research
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manuscript.
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Figure 1 Indirect immunoperoxidase staining of transitional cell
carcinoma of bladder using antibody CBII, showing membrane
positivity.
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